Search

Displaying results 4701 - 4710 of 10000 in total
  1. Drug

    MDX-1303

    go.drugbank.com/drugs/DB05945
    Investigational

    toxins known as the anthrax protective antigen. … MDX-1303 is a fully human antibody against the inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium, and targets a protein component of these lethal

  2. Drug

    RAV12

    go.drugbank.com/drugs/DB05140
    Investigational

    RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid. … RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.

  3. Drug

    Morinamide

    go.drugbank.com/drugs/DB13417
    Investigational

    Categories: Antiinfectives for Systemic Use
  4. Drug

    Tosufloxacin

    go.drugbank.com/drugs/DB16850
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    R673

    go.drugbank.com/drugs/DB05466
    Experimental

    The phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning … R673 is a novel NK1 antagonist that penetrates the blood-brain barrier, has excellent safety and tolerability and shows low P450-based drug interaction potential.

  6. Drug

    Palifosfamide

    go.drugbank.com/drugs/DB05668
    Investigational

    Palifosfamide (ZIO-201) is a proprietary stabilized metabolite of ifosfamide. Ifosfamide has been shown to be effective in high doses in treating testicular cancer, sarcoma and lymphoma.

  7. Drug

    Dirucotide

    go.drugbank.com/drugs/DB04921
    Investigational

    Dirucotide is a synthetically prepared peptide. In particular, the sequence prepared is a 17 amino acid chain that is identical to a section of myelin basic protein (MBP) that is found in humans. … Dirucotide has been developed for the treatment of multiple sclerosis (MS). Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp.

  8. Drug

    DDP-200

    go.drugbank.com/drugs/DB05919
    Experimental

    DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia

  9. Drug

    Difluprednate

    go.drugbank.com/drugs/DB06781
    ApprovedInvestigational

    Difluprednate is abbreviated DFBA, or difluoroprednisolone butyrate acetate. It is indicated for treatment of endogenous anterior uveiti. … Difluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate.

  10. Drug

    GT 389-255

    go.drugbank.com/drugs/DB05894
    Experimental

    It is expected to block fat absorption with fewer side effects than currently marketed lipase inhibitors. … Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and